Mendel Goldfinger
@MendelGoldfing2
Followers
47
Following
2
Media
0
Statuses
5
RT @aditishasMD: Very excited to have contributed to this innovative trial with reassuring data esp for TP53 mutant MDS / AML lead by @Mend….
0
5
0
RT @Saunthararajah: Giving drugs by minimums to engage targets (not more!) can increase both quality- (less side-effects) and quantity-of-l….
ashpublications.org
When an entirely new class of drug such as BCL2 inhibitors enters practice, optimizing benefits and reducing risks typically require exploration beyond reg
0
6
0
🔥 Our clinical trial of metronomic low-dose decitabine-ven in frontline MDS/ AML shows low tox, high efficacy & high response rate in TP53 mutant pts!! @Amitvermamds @aditishasMD @YannisMantz @mkonople @Saunthararajah @MontefioreNYC @EinsteinMed #leusm.
pubmed.ncbi.nlm.nih.gov
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall...
2
23
45
RT @EinsteinMed: Montefiore Einstein Cancer Center Finds CAR-T Therapy effective in Black and Hispanic Patients. New Research finds no stat….
0
1
0